MAI Capital Management’s Pacira BioSciences PCRX Stock Holding History

MAI Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.55K	Buy	+113	New	+$2.51K	﹤0.01%	3835

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MAI Capital Management's PCRX Position: Q1 2026 in Review

MAI Capital Management opened a new position in Pacira BioSciences (PCRX) in Q1 2026: 113 shares worth $2.55K. The stake represents ﹤0.01% of the portfolio and ranks #3835 among its holdings.

241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

MAI Capital Management held 113 shares of Pacira BioSciences worth $2.55K as of Q1 2026.
Pacira BioSciences was a new MAI Capital Management position in Q1 2026.
Pacira BioSciences made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #3835 holding.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.